Invasive candidiasis in liver transplant recipient: Early rescue antifungal treatment;Candidiasis invasora en un receptor de trasplante hepático: tratamiento antifúngico de rescate precoz

Revista Iberoamericana de Micologia

Volumn 28, Issue 3, 2011, Pages 124-128

  Pozo Laderas, Juan Carlos ^a,b,c   Pontes Moreno, y Antonio ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b Maimonides Institute for Research in Biomedicine of Cordoba   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Liver transplant Invasive fungal infection Candida Antifungal agents

Indexed keywords

ANIDULAFUNGIN;

ARTICLE; CANDIDA; CANDIDEMIA; EARLY INTERVENTION; GRAFT RECIPIENT; HIGH RISK PATIENT; HUMAN; INVASIVE CANDIDIASIS; LIVER GRAFT; POSTOPERATIVE PERIOD; PROGNOSIS; RISK FACTOR; SENSITIVITY ANALYSIS;

ACUTE KIDNEY INJURY; ADULT; ANTIFUNGAL AGENTS; BACTEREMIA; BLOOD LOSS, SURGICAL; CANDIDEMIA; CROSS INFECTION; EARLY DIAGNOSIS; ECHINOCANDINS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOCOMPROMISED HOST; LIVER CIRRHOSIS, ALCOHOLIC; LIVER TRANSPLANTATION; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; OPPORTUNISTIC INFECTIONS; POSTOPERATIVE COMPLICATIONS; RENAL DIALYSIS; REOPERATION; RISK; STAPHYLOCOCCAL INFECTIONS;

CANDIDA;

EID: 79959335165     PISSN: 11301406     EISSN: 21739188     Source Type: Journal    
DOI: 10.1016/j.riam.2011.06.004     Document Type: Article

References (52)

1. Andes D., Diekema D.J., Pfaller M.A., Bohrmuller J., Marchillo K., Lepak A. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob Agents Chemother. 2010, 54:2497-2506.
2. Andes D., Diekema D.J., Pfaller M.A., Prince R.A., Marchillo K., Ashbeck J., et al. In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. Antimicrob Agents Chemother. 2008, 52:539-550.
3. Andes D., Marchillo K., Lowther J., Bryskier A., Stamstad T., Conklin R. In vivo phar-macodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model. Antimicrob Agents Chemother. 2003, 47:1187-1192.
4. Arendrup M.C., Cuenca-Estrella M., Donnelly J.P., Lass-Flörl C., Rodriguez-Tudela J.L. Association of fluconazole pharmacodynamics with mortality in patients with candidemia. Antimicrob Agents Chemother. 2009, 53:2704-2705.
5. Arendrup M.C., Garcia-Effron G., Lass-Flörl C., Lopez A.G., Rodriguez-Tudela J.L., Cuenca-Estrella M., et al. Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3. Etest, disk diffusion, and agar dilution methods with RPMI and isosensitest media. Antimicrob Agents Chemother. 2010, 54:426-439.
6. Avni T., Leibovici L., Paul M. PCR diagnosis of invasive candidiasis: systematic review and meta-analysis. J Clin Microbiol. 2011, 49:665-670.
7. Badiee R., Kordbacheh R., Alborzi A., Malekhoseini S., Zeini F., Mirhendi H., et al. Prospective screening in liver transplant recipients by panfungal PCR-ELISA for early diagnosis of invasive fungal infections. Liver Transpl. 2007, 13:1011-1016.
8. Bellomo R., Ronco C., Kellum J.A., Mehta R.L., Palevsky P. ADQI workgroup: Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004, 8:R204-R212.
9. Cruciani M., Mengoli C., Malena M., Bosco O., Serpelloni G., Grossi P. Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis. Liver Transpl. 2006, 12:850-858.
10. Cuenca-Estrella M., Lee-Yang W., Ciblak M.A., Arthington-Skaggs B.A., Mellado E., War-nock D.W., et al. Comparative evaluation of NCCLS M27-A and EUCAST broth micro-dilution procedures for antifungal susceptibility testing of candida species. Antimicrob Agents Chemother. 2002, 46:3644-3647.
11. Cuesta I., Bielza C., Cuenca-Estrella M., Larrañaga P., Rodríguez-Tudela J.L. Evaluation by data mining techniques of fluconazole breakpoints established by the Clinical and Laboratory Standards Institute (CLSI) and comparison with those of the Euro-pean Committee on Antimicrobial Susceptibility Testing (EUCAST). Antimicrob Agents Chemother. 2010, 54:1541-1546.
12. Cuesta I., Bielza C., Larrañaga P., Cuenca-Estrella M., Laguna F., Rodriguez-Pardo D., et al. Data mining validation of fluconazole breakpoints established by the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother. 2009, 53:2949-2954.
13. De Pauw B., Walsh T.J., Donnelly J.P., Stevens D.A., Edwards J.E., Calandra T., et al. European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Stud y G roup (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008, 46:1813-1821.
14. Fortún J., Martín-Dávila R., Montejo M., Muñoz P., Cisneros J.M., Ramos A., et al. GESI-TRA Study Group. Prophylaxis with caspofungin for invasive fungal infections in high-risk liver transplant recipients. Transplantation. 2009, 87:424-435.
15. Garey K.W., Pai M.P., Suda K.J., Turpin R.S., Rege M.D., Mingo D.E., et al. Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines. Pharmacoepidemiol Drug Saf. 2007, 16:919-927.
16. Garey K.W., Rege M., Pai M.P., Mingo D.E., Suda K.J., Turpin R.S., et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006, 43:25-31.
17. George B.J., Horvath L.L., Hospenthal D.R. Effect of inoculum size on detection of Candida growth by the BACTEC 9240 automated blood culture system using aerobic and anaerobic media. J Clin Microbiol. 2005, 43:433-435.
18. Guinea J., Recio S., Escribano P., Torres-Narbona M., Peláez T., Sánchez-Carrillo C., et al. Rapid antifungal susceptibility determination for yeast isolates by use of Etest performed directly on blood samples from patients with fungemia. J Clin Microbiol. 2010, 48:2205-2212.
19. Horvath L.L., George B.J., Hospenthal D.R. Detection of fifteen species of Candida in an automated blood culture system. J Clin Microbiol. 2007, 45:3062-3064.
20. Horvath L.L., Hospenthal D.R., Murray C.K., Dooley D.P. Detection of simulated candidemia by the BACTEC 9240 system with plus aerobic/F and anaerobic/F blood culture bottles. J Clin Microbiol. 2003, 41:4714-4717.
21. Humar A., Michaels M., ID A.S.T. Working Group on Infectious Disease Monitoring American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant. 2006, 6:262-274.
22. Kusne S., Tobin D., Pasculle A.W., Van Thiel D.H., Ho M., Starzl T.E. Candida carriage in the alimentary tract of liver transplant candidates. Transplantation. 1994, 57:398-402.
23. Lepak A., Andes D. Fungal sepsis: optimizing antifungal therapy in the critical care setting. Crit Care Clin. 2011, 27:123-147.
24. Liu X, Ling Z, Li L, Ruan B. Invasive fungal infections in liver transplantation. Int J Infect Dis. 2011. doi:10.1016/j.ijid.2011.01.005.
25. MacCallum D.M., Odds F.C. Need for early antifungal treatment confirmed in experimental disseminated Candida albicans infection. Antimicrob Agents Chemother. 2004, 48:4911-4914.
26. Martini A., Gottin L., Menestrina N., Schweiger V., Simion D., Vincent J.L. Procalcitonin levels in surgical patients at risk of candidemia. J Infect. 2010, 60:425-430.
27. Messer S.A., Diekema D.J., Boyken L., Tendolkar S., Hollis R.J., Pfaller M.A. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. J Clin Microbiol. 2006, 44:324-326.
28. Mills E.J., Perri D., Cooper C., Nachega J.B., Wu R., Tleyjeh I., et al. Antifungal treatment for invasive Candida infections: a mixed treatment comparison meta-analysis. Ann Clin Microbiol Antimicrob. 2009, 8:23.
29. Montravers P, Mira JP, Gangneux JP, Leroy O, Lortholary O. for the AmarCand stu dy gr oup. A multicentre study of antifungal strategies and outcome of Candida spp. peritonitis in intensive-care units. Clin Microbiol Infect. 2010. doi: 10.1111/j.1469-0691.2010.03360.x.
30. Moreno A., Cervera C., Gavaldá J., Rovira M., De la Cámara R., Jarque I., et al. Bloodstream infections among transplant recipients: results of a nationwide surveillance in Spain. Am J Transplant. 2007, 7:2579-2586.
31. Morrell M., Fraser V.J., Kollef M.H. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005, 49:3640-3645.
32. Muñoz P, Rojas L, Cervera C, Garrido G, Fariñas MC, Valerio M, et al. on beh alf of the COMIT Stud y Group. Poor compliance with antifungal drug use guideli-nes by transplant physicians: a framework for educational guidelines and an international consensus on patient safety. Clin Transplant. 2011. doi: 10.1111/j.1399-0012.2011.01405.x.
33. Nguyen K.T., Ta P., Hoang B.T., Cheng S., Hao B., Nguyen M.H., et al. Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata. C. parapsilosis, and C. krusei isolates. Antimicrob Agents Chemother. 2009, 53:3347-3352.
34. Obayashi T., Negishi K., Suzuki T., Funata N. Reappraisal of the serum (1- ->3)-beta-D-glucan assay for the diagnosis of invasive fungal infections - a study based on autopsy cases from 6 years. Clin Infect Dis. 2008, 46:1864-1870.
35. Pappas P.G., Alexander B.D., Andes D.R., Hadley S., Kauffman C.A., Freifeld A., et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis. 2010, 50:1101-1111.
36. Pappas P.G., Andes D., Schuster M., Hadley S., Rabkin J., Merion R.M., et al. Invasive fungal infections in low-risk liver transplant recipients: a multi-center prospective observational study. Am J Transplant. 2006, 6:386-391.
37. Pappas P.G., Kauffman C.A., Andes D., Benjamin D.K., Calandra T.F. Edwards JEJr, et al; Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009, 48:503-535.
38. Pemán J., Cantón E., Gobernado M., Spanish ECMM W orking Group on Candidaemia. Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multicentre study in Spain. Eur J Clin Microbiol Infect Dis. 2005, 24:23-30.
39. Pemán J, Cantón E, Camarena Miñana JJ, Alcoba Florez J, EcheverriaJ, Navarro Ortega D, et al. Variación de la epidemiologia de las fungemias y de la sensibilidad a fluco-nazol de los aislamientos en los últimos 10 años en España: resultados del estudio FUNGEMYCA. Rev Iberoam Micol. 2011; 28:doi:10.1016/j.riam.2011.02.005.
40. Pemán J., Zaragoza R., Quindós G., Alkorta M., Cuétara M.S., Camarena J.J., et al. the stud y group Candida albicans Germ Tube Antibody Detection in Critically Ill Patients (CAGTAUCI). Clinical factors associated with a Candida albicans germ tube antibody positive test in Intensive Care Unit patients. BMC Infect Dis. 2011, 11:60.
41. Pfaller M.A., Boyken L., Hollis R.J., Messer S.A., Tendolkar S., Diekema D.J. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J Clin Microbiol. 2005, 43:5425-5427.
42. Pfaller MA, Diekema DJ, Andes D, Arendrup MC, Brown SD, Lockhart SR, et al. the CLSI Subcommittee for Antifungal Testing. Clinical breakpoints for the echinocan-dins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat. 2011 doi:10.1016/j.drup.2011.01.004.
43. Pfaller M.A., Diekema D.J., Gibbs D.L., Newell V.A., Ellis D., Tullio V., et al. and the Global Antifungal Surveillance Group. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10. 5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol. 2010, 48:1366-1377.
44. Pfaller M.A., Espinel-Ingroff A., Boyken L., Hollis R.J., Kroeger J., Messer S.A., et al. Comparison of the Broth Microdilution (BMD) Method of the European Committee on Antimicrobial Susceptibility Testing with the 24-hour CLSI BMD method for testing susceptibility of Candida species to fluconazole, posaconazole, and voriconazole by use of epidemiological cutoff values. J Clin Microbiol. 2011, 49:845-850.
45. Pierrakos C., Vincent J.L. Sepsis biomarkers: a review. Crit Care. 2010, 14:R15.
46. Playford E.G., Webster A.C., Sorell T.C., Craig J.C. Antifungal agents for preventing fungal infections in solid organ transplant recipients. Cochrane Database Syst Rev. 2004, CD004291.
47. Pontón J., Del Palacio A. Avances y limitaciones del diagnóstico precoz de las infec-ciones invasoras causadas por levaduras. Rev Iberoam Micol. 2007, 24:181-186.
48. Pozo Laderas J.C. Profilaxis antifúngica en receptores de trasplante hepático VIH seropositivos. Rev Iberoam Micol. 2011, 28. [En prensa].
49. RexJH, Pfaller M.A. Has antifungal susceptibility testing come of age?. Clin Infect Dis. 2002, 35:982-989.
50. Stein G.E., El-Mortada M., Smith C., Dybas L., Prince R., Havlichek D. Fungicidal activity of anidulafungin in serum from patients does not correlate to its susceptible breakpoint against Candida spp. J Antimicrob Chemother. 2010, 65:374-376.
51. Wang J.L., Chang C.H., Young-Xu Y., Chan K.A. Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection. Antimicrob Agents Chemother. 2010, 54:2409-2419.
52. Winston D.J., Pakrasi A., Busuttil R.W. Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1999, 131:729-737.